Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
19000
¥ millionWording
Conditional
How definitive the wording is.Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSNet Sales2,042,439¥ millionYear on year +12.3%Progress 75.0%
Operating profit423,733¥ millionYear on year +4.0%Progress 86.8%
Ordinary income422,273¥ millionYear on year +7.5%Progress 86.2%
Net income attributable to owners of the parent322,105¥ millionYear on year +8.2%Progress 87.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥612.03
Financial position at period-end
Total assets4,323,273¥ million
of which net assets 3,285,658 ¥ millionEquity ratio 74.4%vs. prior year-end +2.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+334,168
Investment-206,203
Financials-191,364
Net change-63,399
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥472,489 million
Segment revenueMedical-related business ¥1,460,575 million (YoY +14.2%), Nutraceutical business ¥460,631 million (YoY +6.9%), Consumer products business ¥26,967 million (YoY +4.5%), Other businesses ¥97,033 million (YoY +12.8%)
Segment profitMedical-related business ¥380,241 million (YoY +2.3%), Nutraceutical business ¥55,965 million (YoY +15.3%), Consumer products business ¥24,483 million (YoY +15.4%), Other businesses ¥7,202 million (YoY +1.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥2,725,000 million (YoY +10.4%)
Operating profit¥488,000 million (YoY +1.8%)
Ordinary income¥490,000 million
Net income¥370,000 million (YoY +1.9%)
Profit for the period¥375,000 million (YoY +2.4%)
Business profit¥500,000 million (YoY +12.1%)
Revision to Earnings ForecastRevenue ¥2,725,000 million → ¥2,725,000 million / Business profit before R&D investment ¥855,000 million → ¥873,000 million（+2.1%） / Business profit ¥470,000 million → ¥500,000 million（+6.4%） / Operating profit ¥469,000 million → ¥488,000 million（+4.1%） / Profit before tax ¥472,000 million → ¥490,000 million（+3.8%） / Profit for the period ¥360,000 million → ¥375,000 million（+4.2%） / Profit for the period attributable to owners of the parent ¥355,000 million → ¥370,000 million（+4.2%） / R&D expenses ¥385,000 million → ¥373,000 million（-3.1%）
Annual Dividend Forecast¥140 → ¥200（+42.9%）
Factors Behind Changes in Business Performance
In the healthcare-related business, growth in prescriptions and revenue for Rexulti, Lonsurf, Abilify products and Voyzact, increased royalty income, and the launch of the infusion business in the United States contributed to higher revenue. In the nutraceuticals-related business, all 3 categories based on social issues grew. The increase in operating profit was due to an increase in business profit.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew Number of companies 2 / Company name Otsuka Clinical Nutrition America LLC, Transcend Therapeutics, Inc. / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsAt its meeting held on 30 October 2026, the Board of Directors resolved to cancel 4,537,700 treasury shares on 11 December 2026. The total number of issued shares after the cancellation will be 538,451,217.
Impairment loss¥14,750 million
Depreciation and amortization¥91,107 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors, securities analysts and members of the press)
Issued Shares at Period-End542,988,917 shares
Treasury Shares at Period-End19,081,004 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥2,042,439 million (YoY +12.3%) |
| Operating profit | ¥423,733 million (YoY +4.0%) |
| Ordinary income | ¥422,273 million (YoY +7.5%) |
| Profit attributable to owners of the parent | ¥322,105 million (YoY +8.2%) |
| Net income per share | ¥612.03 |
| Equity ratio | End of the current fiscal period 74.4 / End of previous period 72.3 |
| Total assets | ¥4,323,273 million |
| Net assets | ¥3,285,658 million |
| Cash flows from operating activities | ¥334,168 million |
| Cash flows from investing activities | ¥-206,203 million |
| Cash flows from financing activities | ¥-191,364 million |
| Cash and cash equivalents at end of period | ¥472,489 million |
| Full-year earnings forecast | Net Sales ¥2,725,000 million (YoY +10.4%) / Operating profit ¥488,000 million (YoY +1.8%) / Ordinary income ¥490,000 million / Net income ¥370,000 million (YoY +1.9%) / Profit for the period ¥375,000 million (YoY +2.4%) / Business profit ¥500,000 million (YoY +12.1%) |
| Revision to Earnings Forecast | Revenue ¥2,725,000 million → ¥2,725,000 million / Business profit before R&D investment ¥855,000 million → ¥873,000 million（+2.1%） / Business profit ¥470,000 million → ¥500,000 million（+6.4%） / Operating profit ¥469,000 million → ¥488,000 million（+4.1%） / Profit before tax ¥472,000 million → ¥490,000 million（+3.8%） / Profit for the period ¥360,000 million → ¥375,000 million（+4.2%） / Profit for the period attributable to owners of the parent ¥355,000 million → ¥370,000 million（+4.2%） / R&D expenses ¥385,000 million → ¥373,000 million（-3.1%） |
| Annual Dividend Forecast | ¥140 → ¥200（+42.9%） |
| Segment revenue | Medical-related business ¥1,460,575 million (YoY +14.2%), Nutraceutical business ¥460,631 million (YoY +6.9%), Consumer products business ¥26,967 million (YoY +4.5%), Other businesses ¥97,033 million (YoY +12.8%) |
| Segment profit | Medical-related business ¥380,241 million (YoY +2.3%), Nutraceutical business ¥55,965 million (YoY +15.3%), Consumer products business ¥24,483 million (YoY +15.4%), Other businesses ¥7,202 million (YoY +1.1%) |
| Depreciation and amortization | ¥91,107 million |
| Impairment loss | ¥14,750 million |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 2 / Company name Otsuka Clinical Nutrition America LLC, Transcend Therapeutics, Inc. / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | At its meeting held on 30 October 2026, the Board of Directors resolved to cancel 4,537,700 treasury shares on 11 December 2026. The total number of issued shares after the cancellation will be 538,451,217. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors, securities analysts and members of the press) |
| Issued Shares at Period-End | 542,988,917 shares |
| Treasury Shares at Period-End | 19,081,004 shares |
| Factors Behind Changes in Business Performance | In the healthcare-related business, growth in prescriptions and revenue for Rexulti, Lonsurf, Abilify products and Voyzact, increased royalty income, and the launch of the infusion business in the United States contributed to higher revenue. In the nutraceuticals-related business, all 3 categories based on social issues grew. The increase in operating profit was due to an increase in business profit. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogBreakdown of extraordinary income (loss)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Rexulti, Voyzact and other products in the healthcare-related business performed well, and gross profit exceeded the previous forecast. Expenses were controlled in selling, general and administrative expenses, and research and development expenses are expected to come in below the previous forecast.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.